Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Controlled, Double-blind Pivotal Phase 3 Trial to Evaluate the Safety and Immunogenicity of a Live-attenuated Chikungunya Virus Vaccine (VLA1553) in Healthy Children Aged 1 to 11 Years

NCT07133178 is registered in ClinicalTrials.gov with Valneva Austria GmbH as lead sponsor.

NCT NCT07133178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07133178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Controlled, Double-blind Pivotal Phase 3 Trial to Evaluate the Safety and Immunogenicity of a Live-attenuated Chikungunya Virus Vaccine (VLA1553) in Healthy Children Aged 1 to 11 Years
Lead sponsor
Valneva Austria GmbH
Phase
Phase 3
Overall status
Withdrawn
Start date
February 6, 2026
Completion date
November 30, 2027
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chikungunya virus infection